1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Employee Stock Option (right to buy)
|
06/07/2006 |
06/07/2016 |
Common Stock
|
4,752
(1)
(2)
|
$
0.2683
(3)
(4)
|
D
|
|
Employee Stock Option (right to buy)
|
04/27/2007 |
04/27/2017 |
Common Stock
|
932
(1)
(2)
|
$
0.2683
(3)
(4)
|
D
|
|
Employee Stock Option (right to buy)
|
12/06/2007 |
12/06/2017 |
Common Stock
|
634
(2)
(5)
|
$
0.2683
(3)
(4)
|
D
|
|
Employee Stock Option (right to buy)
|
11/18/2008 |
11/18/2018 |
Common Stock
|
327
(2)
(6)
|
$
0.2683
(3)
(4)
|
D
|
|
Employee Stock Option (right to buy)
|
06/09/2010 |
06/09/2020 |
Common Stock
|
3,177
(2)
(7)
|
$
0.2683
(3)
(4)
|
D
|
|
* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
100% of the options have vested. |
(2) |
These options vest semi-annually over four years from the date of grant. |
(3) |
Amended to correct mistake in option exercise price after appropriate application of conversion ratio as explained in footnotes. |
(4) |
Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each share of AC common stock converted into 0.03727336 share of LecTec common stock at the effective time of the Merger. In connection with the Merger, each option to purchase shares of AC common stock was converted tor an option to purchase 0.03727336 of a share of AxoGen common stock. |
(5) |
555 options have vested, and 79 options are unvested. |
(6) |
204 options have vested, and 123 options are unvested. |
(7) |
794 options have vested, and 2,383 options are unvested. |